Jiangsu Hualan New Pharmaceutical Material Co.,Ltd. (SHE:301093)
China · Delayed Price · Currency is CNY 47.68
-2.28 (-4.56%)
Oct 27, 2026, 4:00 PM EDT
SHE:301093 Revenue
Jiangsu Hualan New Pharmaceutical Material had revenue of 168.48M CNY in the quarter ending June 30, 2026, with 3.25% growth. This brings the company's total for the last twelve months to 608.73M, down -0.44% year-over-year. In the year 2025, Jiangsu Hualan New Pharmaceutical Material had annual revenue of 619.45M with 5.63% growth. That makes Jiangsu Hualan New Pharmaceutical Material the 23,375th largest company in the world by revenue and 4,238th in China.
Revenue (ttm)
608.73M
Revenue Growth
-0.44%
P/S Ratio
16.68
Revenue / Employee
n/a
Employees
945
Market Cap
10.16B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:301093 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 619.45M | 33.04M | 5.63% |
| Dec 31, 2024 | 586.41M | -36.51M | -5.86% |
| Dec 31, 2023 | 622.92M | 38.79M | 6.64% |
| Jan 1, 2023 | 584.14M | -236.73M | -28.84% |
| Jan 1, 2022 | 820.87M | 374.54M | 83.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Truking Technology | 5.89B |
| Tofflon Science and Technology Group | 5.34B |
| Micro-Tech (Nanjing) Co.,Ltd | 3.35B |
| Shenyang Xingqi Pharmaceutical | 2.71B |
| Zhonghong Pulin Medical Products | 2.61B |
| Autek China | 1.82B |
| Eyebright Medical Technology (Beijing) | 1.63B |
| Sansure Biotech | 1.61B |